ArticleOphthalmology and therapy2015
The Future of Dry Eye Treatment: A Glance into the Therapeutic Pipeline.
Article in Ophthalmology and therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 19 citations in OpenAlex.
- Animal Models in Eye Research: Focus on Corneal Pathologies.International journal of molecular sciences · 2023Review
- Neurokinin-1 Receptor Antagonism Ameliorates Dry Eye Disease by Inhibiting Antigen-Presenting Cell Maturation and T Helper 17 Cell Activation.The American journal of pathology · 2020Article
- Naltrexone as a Novel Therapeutic for Diabetic Corneal Complications.Journal of cellular immunology · 2020Article
- Dry Eye Disease: A Review of Epidemiology in Taiwan, and its Clinical Treatment and Merits.Journal of clinical medicine · 2019Review
- Efficacy and safety of a novel naltrexone treatment for dry eye in type 1 diabetes.BMC ophthalmology · 2019Article
- Overcoming Obstacles to Drug Repositioning in Japan.Frontiers in pharmacology · 2017Article
- Dry Eye Syndrome in Patients with Diabetes Mellitus: Prevalence, Etiology, and Clinical Characteristics.Journal of ophthalmology · 2016Review
- Corneal sensitivity, ocular surface health and tear film stability after punctal plug therapy of aqueous deficient dry eye.International journal of ophthalmology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dry eye syndrome is both a primary disease and a secondary result of many pathological states of the eye. The symptoms range from mild to severe itching, burning, irritation, eye fatigue, and even vision loss that can lead to disability. Dry eye affects approximately 60 million people worldwide; as a result, medications to treat dry eye comprise approximately 15% of the ophthalmic pharmaceutical market. While doctors and patients eagerly await new treatments, pharmaceuticals in the pipeline are moving through the approval process with several promising drugs having completed phase 3 clinical testing. This review summarizes the findings of studies of the most promising, upcoming dry eye treatments in phase 2 and 3 clinical trials in the USA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.